Technology
Health
Pharmaceutical

Regulus Therapeutics

$1.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-6.03%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RGLS and other stocks, options, ETFs, and crypto commission-free!

About

Regulus Therapeutics Inc. Common Stock, also called Regulus Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Read More Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Employees
24
Headquarters
San Diego, California
Founded
2007
Market Cap
10.15M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
233.93K
High Today
$1.20
Low Today
$1.09
Open Price
$1.13
Volume
50.38K
52 Week High
$10.44
52 Week Low
$0.80

Collections

Technology
Health
Pharmaceutical
Medical
Therapy
Biopharmaceutical
US
North America

News

PR NewswireMar 18

Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates

LA JOLLA, Calif., March 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2018 and provided a corporate update. "2018 was a challenging year for Regulus, but I am encouraged by our program advancements and recent corporate and cost-saving efforts. Importantly, we have nearly completed the trans...

76
Markets InsiderMar 15

Regulus Announces Transition of Research Leadership

LA JOLLA, Calif., March 15, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright, Chief Research and Development Officer, effective March 15, 2019. Dr. Wright is leaving for personal reasons to pursue a new opportunity, and will continue to support Regulus as a scientific advisor. "We appreciate Tim's contributions over the last t...

65
Simply Wall StMar 13

Did You Manage To Avoid Regulus Therapeutics’s (NASDAQ:RGLS) 99% Share Price Wipe Out?

Regulus Therapeutics Inc. (NASDAQ:RGLS) shareholders will doubtless be very grateful to see the share price up 41% in the last month. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. In fact, the share price has tumbled down a mountain to land 99% lower after that period. It’s true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The important question is if the business itself justifies a higher share price in the long term. ...

248

Earnings

-$1.25
-$0.88
-$0.50
-$0.13
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.92 per share
Actual
-$0.98 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.